Join to View Full Profile
3333 N Calvert StSte 600Baltimore, MD 21218
Phone+1 410-467-7665
Fax+1 410-467-7746
Dr. Lowentritt is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of MarylandResidency, Urology, 2001 - 2005- University of MarylandResidency, Surgery, 1999 - 2001
Baylor College of MedicineClass of 1999
Certifications & Licensure
AZ State Medical License 2025 - 2027
CO State Medical License 2025 - 2027
TN State Medical License 2025 - 2027
MD State Medical License 2005 - 2026
LA State Medical License 2005 - 2012
American Board of Urology Urology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification Allscripts Professional EHR, Allscripts, 2011, 2013-2017
- CMS Meaningful Use Stage 2 Certification Medfusion Patient Portal, Medfusion, Inc., 2011, 2013-2017
- CMS Meaningful Use Stage 2 Certification Allscripts Professional EHR, Allscripts, 2011, 2013-2017
Publications & Presentations
PubMed
- Comparison of deep prostate-specific antigen response in Black patients with metastatic castration-sensitive prostate cancer initiated on apalutamide or enzalutamide.Benjamin H Lowentritt, Sabree Burbage, Ibrahim Khilfeh, Dominic Pilon, Shawn Du
Journal of Comparative Effectiveness Research. 2026-02-01 - Homologous Recombination Repair Mutations, Next-generation Sequencing Testing, and Treatment Progression by Race Among Patients With Metastatic Castration-sensitive Pr...Mehmet A Bilen, Neal Shore, Sabree Burbage, Carmine Rossi, Lilian Diaz
Urology. 2026-01-29 - Response to Letter to the Editor Regarding: 'Overall Survival with Apalutamide Versus Enzalutamide in Metastatic Castration-Sensitive Prostate Cancer'.Mehmet A Bilen, Benjamin Lowentritt, Ibrahim Khilfeh, Carmine Rossi, Shawn Du
Advances in Therapy. 2026-01-01
Press Mentions
Physician Resilience Is the Only Way to “Maintain Sanity in This Crazy, Crazy World of Medicine”November 10th, 2025- New ERLEADA® (Apalutamide) Analysis Demonstrates Rapid, Deep Prostate-Specific Antigen (PSA) Response in Patients with Metastatic Castration-Sensitive Prostate Cancer (mCSPC)February 14th, 2022
- (Apalutamide) Oral Presentations Demonstrate Importance of Prostate Specific Antigen (PSA) as Key Efficacy Indicator and Show Strong Patient Adherence RatesSeptember 12th, 2021
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
